For all the talk lately about quality control problems with some drugs made in India, one has to look no further than the nation’s medicine chest for an example of egregious manufacturing practices.

In a lengthy and especially stern warning letter, the Food and Drug Administration scolded Akorn (AKRX) (ACRX) — which has faced long-running production issues at several facilities — for a laundry list of poor actions that was found during an inspection of a New Jersey plant last summer. And the issues bolster the concerns cited by Fresenius for backing away from its $4.7 billion acquisition of the troubled company last year.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy